Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.31 |
| ▸ | EP300 | Q09472 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | CKS1B | P61024 | 1/20 | 0.30 |
| ▸ | SKP1 | P63208 | 1/20 | 0.30 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466796 | 0.91 | SCN9A (0.32) | MCHR1ADRA2AACHE | |
| SCHEMBL6459940 | 0.83 | MCHR1 (0.40) | SLC2A1MCHR1ADRA2ANPY5RVCP | |
| SCHEMBL6457323 | 0.79 | MCHR1 (0.48) | MCHR1ADRA2ANPY5R | |
| SCHEMBL6873895 | 0.79 | MCHR1 (0.43) | SLC2A1MCHR1ADRA2ANPY5R | |
| SCHEMBL6873890 | 0.79 | MCHR1 (0.43) | SLC2A1MCHR1ADRA2ANPY5R | |
| Hydrochloric Acid SCHEMBL6457797 | 0.78 | MCHR1 (0.47) | MCHR1ADRA2ANPY5R | |
| SCHEMBL6462321 | 0.76 | GAA (0.34) | SLC2A1MCHR1ADRA2ANPY5RACHE | |
| SCHEMBL6462228 | 0.74 | CDK1 (0.33) | MCHR1ADRA2ANPY5R | |
| SCHEMBL13796887 | 0.74 | MCHR1 (0.61) | MCHR1ADRA2ANPY5R | |
| SCHEMBL6460351 | 0.72 | CD274 (0.33) | MCHR1ADRA2ANPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | claimed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | claimed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | SLC2A1 2329/4885MCHR1 2/4885ADRA2A 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.